ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2320

Pediatric Rheumatology Infusion Center: Report on Therapeutic Protocols and Infusion Reactions over 4 Years

Annelle Reed1, Surabhi S. Vinod2, Jamelle Maxwell3, Esraa M. A. Eloseily4,5, Matthew L. Stoll4 and Randy Q. Cron4, 1Pediatric rheumatology, Childrens of Alabama, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3Childrens of Alabama, Birmingham, AL, 4Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 5Pediatrics, Assiut University, Assiut, Egypt

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Adverse events, infliximab, infusions, intravenous immunoglobulin (IVIG) and rituximab

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 7, 2017

Session Title: ARHP Pediatric Rheumatology – Clinical Aspects Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

The goals of this report are to describe various therapeutic protocols, volume of intravenous (IV) infusions, and associated adverse events at the University of Alabama at Birmingham (UAB) Pediatric Rheumatology Infusion Center from 2012 through 2015.

Methods:

This was an institutional review board (IRB) approved retrospective chart review of 7,585 IV infusions given to 398 patients from 2012-2015. Infusion medications included abatacept, belimumab, cyclophosphamide, immune globulin (IVIG), infliximab, methylprednisolone, N-acetylcysteine, pamidronate disodium, rituximab, and tocilizumab. For calendar year 2015, all adverse reactions were recorded along with management strategies and outcomes. Rates of adverse events were calculated per infusion medication.

Results:

During calendar year 2015, 234 patients received 2,181 infusions. Newer biologics (other than IVIG) represented 59% of the total IV infusions given. Of the 234 patients, 37 experienced 45 infusion reactions. The total adverse event rate for all infusions was 2%. Medications with infusion reactions were abatacept, infliximab, immune globulin, methylprednisolone, rituximab, and tocilizumab. Rituximab had the highest rate of adverse drug reactions with 11 patients experiencing reactions during 107 infusions (10%), mainly allergic in nature, while infliximab had the lowest rate of those with reactions with 7 adverse events occurring from 818 infusions (0.8%). All reactions were mild and resolved on slowing the infusion rate and treatment with antihistamines, corticosteroids, analgesics, anti-emetics, or epinephrine as needed.

Conclusion:

In recent years, the UAB Pediatric Rheumatology Infusion Center has treated a wide variety of diagnoses and given thousands of IV infusion. Adverse reactions were few and mostly mild and transient. The use of standardized infusion protocols, the experience of managing physicians and nurses, along with the safety of the medications themselves, allow for safe IV infusions for pediatric rheumatology patients, and provide examples for similar and future infusion centers. Of note, this study does not explore potential later events, such as cancer or tuberculosis, for example.

Table 1. Diagnoses Treated from 2012-2015

 

Diagnosis

Patients (n)

Juvenile Idiopathic Arthritis

174

     Oligoarticular

36

     Polyarticular RF+

50

     Polyarticular RF-

6

     Psoriatic

20

     Enthesitis related arthritis

38

     Systemic

16

     Unspecified

8

Systemic Lupus Erythematosus

64

Juvenile Dermatomyositis

26

Inflammatory Bowel Disease Related Arthritis

26

     Crohn Disease

19

     Ulcerative Colitis

7

Uveitis

20

Sjogren Syndrome

15

Granulomatosis with Polyangitis

11

Henoch-Schonlein Purpura

7

Sarcoidosis

6

Common Variable Immunodeficiency

6

Mixed Connective Tissue Disease

5

Others

37

 

Table 2. Total Infusions given from 2012-2015 listed by medication

Infusions 2012-2015

Total

Infliximab

3,076

Methylprednisolone

1,882

Immune globulin

842

Abatacept

699

Rituximab

370

Cyclophosphamide

359

Tocilizumab

292

Belimumab

34

Pamidronate Disodium

25

N-acetylcysteine

6

Total

7,585

Table3. Number of infusion reactions in 2015

Infusion Reaction (Infusion #)

Abatacept

(237)

IVIG

 (266)

Infliximab

 (818)

Methylprednisolone (516)

Rituximab

(107)

Tocilizumab (140)

Total Infusion Reactions

Rash

 

1

 

 

1

 

2

Nausea/Vomiting

 

3

1

4

1

1

10

Cough

 

1

1

1

2

 

5

Throat Tightness/Itching/Pain

2

2

 

1

5

 

10

Generalized Itching

 

1

 

 

 

 

1

Chest Pain/Tightness

 

1

1

1

 

 

3

Headache

2

3

1

 

 

 

6

Swelling

 

 

2

 

1

 

3

Wheezing

 

 

 

1

 

 

1

Hives

 

 

 

 

1

 

1

Blurry Vision

 

 

 

 

 

1

1

Abdominal Pain

 

 

1

 

 

 

1

Diminished Breath Sounds

1

 

 

 

 

 

1

Total Events

5

12

7

8

11

2

45

 

 

 

 

 

 


Disclosure: A. Reed, None; S. S. Vinod, None; J. Maxwell, None; E. M. A. Eloseily, None; M. L. Stoll, Novartis Pharmaceutical Corporation, 5; R. Q. Cron, SOBI, 5.

To cite this abstract in AMA style:

Reed A, Vinod SS, Maxwell J, Eloseily EMA, Stoll ML, Cron RQ. Pediatric Rheumatology Infusion Center: Report on Therapeutic Protocols and Infusion Reactions over 4 Years [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/pediatric-rheumatology-infusion-center-report-on-therapeutic-protocols-and-infusion-reactions-over-4-years/. Accessed February 25, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pediatric-rheumatology-infusion-center-report-on-therapeutic-protocols-and-infusion-reactions-over-4-years/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.